Stadt Wien Wiener Gesundheitsverbund
- Address
- lock Available on a paid plan
Cardiovascular Disease Research
At Stadt Wien Wiener Gesundheitsverbund, clinical trials in cardiovascular diseases focus on improving care for people at high risk of heart attack and stroke, as well as those living with heart failure and kidney impairment. These studies are designed to assess whether new treatments can better reduce serious cardiovascular events and support long-term heart health.
- Testing therapies to lower the risk of cardiovascular death, myocardial infarction, and ischemic stroke
- Evaluating treatment options for heart failure in patients with impaired kidney function
- Studying preventive strategies for adults with elevated cardiovascular risk
Research in this area aims to improve both prevention and treatment, with a strong emphasis on reducing major complications in everyday cardiac care.
Oncology and Hematology Trials
The site’s Oncology and Hematology Department is actively involved in trials for several cancers and blood disorders, including multiple myeloma, chronic lymphocytic leukemia, urothelial carcinoma, renal cell carcinoma, and prostate cancer. These studies are exploring new treatment combinations and comparing them with current standard therapies to improve survival and disease control.
- Evaluating new approaches for relapsed or refractory multiple myeloma
- Comparing therapies for chronic lymphocytic leukemia/small lymphocytic lymphoma
- Studying treatment strategies for advanced urothelial carcinoma and metastatic castrate-resistant prostate cancer
- Assessing novel options for advanced renal cell carcinoma
These trials are centered on finding more effective and better-tolerated therapies for difficult-to-treat malignancies.
Immune-Mediated and Rheumatologic Research
Clinical research in immune system diseases at this hospital includes studies in rheumatoid arthritis, where investigators are comparing newer treatment approaches with established options. The goal is to better control inflammation, improve symptoms, and help patients maintain daily function.
- Comparing therapies for rheumatoid arthritis
- Assessing how newer immune-targeted treatments may improve disease management
- Exploring safer and more effective options for chronic inflammatory disease
This area reflects a broader effort to refine treatment choices for long-term autoimmune conditions.
Nervous System Disease Studies
The site also contributes to research in nervous system diseases, including Parkinson’s disease. These trials are aimed at evaluating whether investigational therapies can better manage symptoms or slow disease progression compared with placebo or current care.
- Studying potential therapies for Parkinson’s disease
- Assessing symptom control and disease-modifying potential
- Supporting development of improved options for neurodegenerative care
Work in this field is focused on advancing treatment possibilities for patients facing progressive neurological illness.
Metabolic and Supportive Care Research
Trials in nutritional and metabolic diseases at Stadt Wien Wiener Gesundheitsverbund include studies that examine how lipid-lowering and other preventive therapies may reduce future complications in people with high cardiovascular risk. This research supports better management of underlying metabolic risk factors that contribute to serious disease.
- Evaluating therapies for people with elevated cardiovascular risk
- Studying prevention-focused approaches to reduce major vascular events
- Improving long-term management of metabolic and related cardiovascular conditions
These studies aim to strengthen prevention strategies and help lower the burden of chronic disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 10 therapeutic areas and 15 of 159 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 158 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 31 by active trials.
- 1AstraZeneca AB5active
lock +30 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB9trials
lock +23 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Stadt Wien Wiener Gesundheitsverbund
lock Showing 1 of 97 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17 | University Of Cologne | Phase III | Not Recruiting | Feb 2021 | — |
IMP list
lock Showing 1 of 159 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 21 | Unknown | 2018-04-04 | 2026-02-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.